Asston Pharmaceuticals Ltd

Change in registered office

• Old registered office: Balaji Bhavan, CBD Belapur, Navi Mumbai (400614).
• New registered office: 24 High, Service Road, Nerul, Navi Mumbai (410210).
• Effective date: 15 October 2026.
• Within the local limits of the same city and under the same ROC.
• Board approved the change at the 13 October 2026 meeting.
• Change approved under Regulation 30 LODR.

AGM details

• Date and time: 29 Sept 2026, 12:30 PM; Mode: VC/OAVM.

Resolutions proposed

• Ordinary: Adopt audited financial statements for year ended 31 March 2026 and related reports.
• Ordinary: Re-appoint MD Ashish Narayan Sakalkar by rotation.
• Ordinary: Appoint Panchal SK & Associates as statutory auditors.
• Special: Increase in MD remuneration.
• Special: Increase in WTD and CEO remuneration.
• Special: Increase in non-executive director remuneration.

Voting status

• 1-6: Voting results to be declared within 2 working days and placed on company and NSDL websites.

Director changes

• MD to be re-appointed by rotation: Ashish Narayan Sakalkar.

Auditor appointments

• Statutory auditors: Panchal SK & Associates appointed.

Asston Pharmaceuticals Ltd trading window closed from 01 October 2026 until the completion of 48 hours from the declaration of Unaudited financial results for the Half Year Ended 30 September 2026

Financial performance

• Total income rose to ₹3158.43 lakh for FY2025-26.
• PAT ₹386.52 lakh, up 0.32% YoY.
• Revenue growth of 23.32% YoY.
• EPS ₹4.92 per share.
• IPO oversubscribed ~186 times; 22,41,000 shares issued.
• IPO proceeds ₹27.56 crore raised.
• Unit II commenced commercial production Jan 21, 2026.
• Export earnings ₹2414.68 lakh.

Capital structure

• Authorized share capital ₹11,00,00,000.
• Paid-up capital ₹8,51,23,600.
• Equity shares: 85,12,360.
• IPO proceeds ₹27.56 crore raised; expansion funding.

Governance & board changes

• CFO resignation Oct 13, 2025; Sumit Pawar appointed Mar 30, 2026.
• Company Secretary changed; Rishi Upadhaya appointed Oct 16, 2025.
• Sandip Sharma appointed Independent Director Mar 30, 2026; regularised Apr 28, 2026.
• Statutory auditors Panchal S K & Associates appointed Feb 27, 2026; 5-year term.

Operations & expansion

• Unit II commenced Jan 2026; capacity expansion active.
• Nutraceuticals added via Unit II; broader product mix.
• Manufacturing capacity expansion supports future growth.

Markets & outlook

• Geographic expansion; Africa footprint; registrations expected in Cambodia and Vietnam.
• Export focus; strengthening international markets.
• Outlook: expand capacity, strengthen relationships, maintain regulatory compliance.

Dividends & capital allocation

• Dividend policy: no dividend for FY2025-26.
• CSR: spent ₹6.23 lakh; PM CARES transfer.

Audit, controls & disclosures

• Internal controls are adequate; no material weaknesses observed.
• Secretarial audit: Pragya & Associates; no qualifications.
• CSR reporting in Annexure-B; BRSR not applicable.

Post year-end developments

• Post-year-end: proposed preferential issue of 24,10,431 equity shares at ₹115 each.
• BSE in-principle approval for preferential issue; may impact paid-up capital.

AGM Details

• AGM date/time/mode: 29 September 2026 at 12:30 PM via VC/OAVM.
• Cut-off date for voting: 22 September 2026.

Ordinary Business

• Adopt audited standalone financial statements for year ended March 31, 2026.
• Appoint Ashish Narayan Sakalkar as Director, retiring by rotation.

Auditor Appointment

• Reappoint M/s Panchal S K & Associates as Statutory Auditors for five-year term.

Special Remuneration Approvals

• MD remuneration increased to six lakh fifty thousand per month from Oct 2026 to Sep 2029.
• WTD/CEO remuneration increased to six lakh fifty thousand per month in same period.
• Non-Executive Director remuneration increased to two lakh fifty thousand per month in same period.
• Remuneration includes expense reimbursement; minimum remuneration allowed in loss years.

Director Tenure Summary

• Ashish Narayan Sakalkar continues as MD for a five-year term.
• Saili Jayaram More continues as Whole-Time Director and CEO for five years.
• Sachin Chandrakant Badakh continues as Non-Executive Director.

Transaction details

• Target Company: Asston Pharmaceuticals Limited.
• Disclosing Party: Prakruti R Pali; non-promoter.
• Transaction Type: Acquisition of voting rights via equity shares.
• Pre-Transaction Holding: 4,54,000 shares, 5.33%.
• Transaction Details: 1,64,000 shares acquired, 1.93%, open market, fully paid equity shares.
• Post-Transaction Holding: 6,18,000 shares, 7.26%.
• Date of Transaction: 28 August 2026.
• Share Capital Context: Before 4,54,000; After 6,18,000; Diluted 6,18,000.

Disclosure details

• Disclosure received by Asston on 31 August 2026 from Mrs. Prakruti R Pali under Reg 29(1) SAST.

Acquisition details

• Target: Asston Pharmaceuticals Limited (BSE SME Platform).
• Acquirer and PAC: Prakruti R Pali; acquirer not promoter.
• Pre-acquisition holding: 2,14,000 shares (2.51%).
• Encumbrances/VRs/warrants: none.
• Acquisition: 2,40,000 shares acquired (2.82%).
• Post-acquisition holding: 4,54,000 shares (5.33%).
• Mode of acquisition: Open Market.
• Date of acquisition: 27 August 2026.
• Equity capital before/after: 2,14,000 -> 4,54,000 shares.
• Salient features: fully paid-up equity shares.

Meeting Details

• Board to meet on Friday, 4 September 2026.

Key Agenda Items

• Appointment of M/s Panchal S K & Associates as Statutory Auditor.
• Consider and ascertain the directors retiring by rotation.
• Increase in remuneration of MD Ashish Narayan Sakalkar.
• Increase in remuneration of Whole Time Director and CEO Saili Jayaram More.
• Increase in remuneration of Non-Executive Director Sachin Chandrakant Badakh.
• Consider and approve the date and draft notice of the 7th AGM.
• Other incidental matters.

Other Notes

• No additional material notes beyond the listed agenda items.

EGM Resolutions

• Special resolution to issue equity shares on a preferential basis.
• Terms such as price, quantity, and allottees were not disclosed in the filing.
• Voting conducted remotely and at EGM; results due within 2 working days; Scrutinizer appointed.